Marketresearch.biz reports that the Generative AI in Pharma market size is expected to be worth around USD 2258.1 Mn by 2033 from USD 159.9 Mn in 2023, growing at a CAGR of 31.2% during the forecast period from 2024 to 2033.Overview of the Generative AI in Pharma MarketGenerative AI in pharma revolutionizes drug dis.
Arctoris Ltd, a tech-enabled biopharma platform company, has appointed three globally recognized experts in Alzheimer's disease, Machine Learning applied to closed loop discovery, and automated chemistry
Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. ("Arctoris"), a tech-enabled biopharma company that combines
Through end-to-end automation, the company’s unique technology platform rapidly delivers reliable, reproducible, and fully auditable datasets
Arctoris Ltd
Ulysses is an advanced, fully automated robotic platform developed and operated by Arctoris that provides superior quality data and accelerates drug discovery.
February 24, 2021
OXFORD, UK February 10, 2021
Life Science Newswire Arctoris Ltd, an Oxford-based technology company operating a fully automated drug discovery platform, celebrated its fifth anniversary on Feb. 4. Over the past five years, Arctoris has grown from a technology startup to a globally operating company delivering integrated drug discovery projects with partners on three continents from its headquarters in Oxford and its Asia-Pacific hub in Singapore. On the occasion of its fifth anniversary, Arctoris unveiled its new and expanded, next-generation robotic platform, Ulysses.